Loading...
•
Jun 30, 2021
DBV Technologies Q2 2021 Earnings Report
DBV Technologies reported financial results for the second quarter of 2021 and provided recent business developments.
Key Takeaways
DBV Technologies reported a net loss of $30.7 million for the second quarter of 2021. The company continues to advance Viaskin Peanut's regulatory dossier and expects its current cash and cash equivalents to support operations until the second half of 2022.
Submitted the protocol for the 6-month adhesion and safety study of the modified patch (STAMP) to the FDA.
Completed a trial in healthy adult volunteers to evaluate the adhesion of five modified Viaskin Peanut patches (CHAMP).
Initiated PREQUAL, a Phase 1 study in healthy adult volunteers to optimize the allergen sample collection methodologies and validate the assays DBV intends to use in EQUAL.
Received from the EMA Day 180 list of outstanding issues.
DBV Technologies
DBV Technologies
Forward Guidance
DBV expects that its current cash and cash equivalents will support its operations until the second half of 2022.